<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656210</url>
  </required_header>
  <id_info>
    <org_study_id>2018_31</org_study_id>
    <secondary_id>2019-A00086-51</secondary_id>
    <nct_id>NCT04656210</nct_id>
  </id_info>
  <brief_title>Myotonic Dystrophy - Vascular and Cognition</brief_title>
  <acronym>MD-VASCOG</acronym>
  <official_title>Links Between Diabetes and Cognitive Impairment in Myotonic Dystrophy Type 1 : a Non-conventional MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cognitive disorders of adult forms of myotonic dystrophies type 1 are heterogeneous&#xD;
      (impairment of executive functions, visio construction and theory of the mind, which can&#xD;
      progress to the stage of dementia). Nevertheless, patients have very different degrees of&#xD;
      cognitive impairment. Expansion of CTG triplets disrupts the alternative splicing of mRNAs of&#xD;
      various proteins, including the insulin receptor and Tau protein. Type 2 diabetes, associated&#xD;
      with peripheral insulin resistance, is therefore common in this pathology.&#xD;
&#xD;
      Type 2 diabetes,could to explain the cognitive impairment of patients, through the&#xD;
      accelerated development of brain lesions (especially tauopathy and cerebral atrophy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrophy difference based on two cerebral MRI volumetries</measure>
    <time_frame>at 4 years</time_frame>
    <description>difference between initial MRI and 4-year MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in scores at 4-year neuropsychological assessment of inclusion</measure>
    <time_frame>At baseline at 4 years</time_frame>
    <description>difference between initial assessment and 4-year assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in tau biomarkers in blood at 4 years of inclusion</measure>
    <time_frame>At baseline at 4 years</time_frame>
    <description>difference between initial and 4-year dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in amyloid biomarkers in blood at 4 years of inclusion</measure>
    <time_frame>At baseline at 4 years</time_frame>
    <description>difference between initial and 4-year dosing</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Myotonic Dystrophy 1</condition>
  <condition>Diabetes</condition>
  <condition>Carbohydrate Intolerance</condition>
  <arm_group>
    <arm_group_label>Group 1: MD type 1 normal</arm_group_label>
    <description>patients with type 1 myotonic dystrophy with normal carbohydrate tolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: MD type 1 Diabetes</arm_group_label>
    <description>patients with type 1 myotonic dystrophy with diabetes. Patients with carbohydrate intolerance (&quot;pre-diabetes&quot;) who became diabetic at 3 years of age will be divided into Group 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Non conventional MRI (35 minutes)</description>
    <arm_group_label>Group 1: MD type 1 normal</arm_group_label>
    <arm_group_label>Group 2: MD type 1 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychological tests</intervention_name>
    <description>Standardized and quantified neuropsychological assessment</description>
    <arm_group_label>Group 1: MD type 1 normal</arm_group_label>
    <arm_group_label>Group 2: MD type 1 Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with DM type 1 monitored annually by the Neuromuscular Disease Reference Centre&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Molecularly proven type 1 myotonic dystrophy&#xD;
&#xD;
          -  Voluntary, having given informed consent&#xD;
&#xD;
          -  Socially insured patient&#xD;
&#xD;
          -  Patient willing to comply with all study procedures and duration (3 hours + MRI 35&#xD;
             minutes)&#xD;
&#xD;
          -  Patient insured under the French social security system&#xD;
&#xD;
          -  Signed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neurological history other than neuropathy: epilepsy, stroke, dementia&#xD;
&#xD;
          -  Pregnancy or breastfeeding or woman of childbearing age without effective&#xD;
             contraception (a pregnancy test will be done)&#xD;
&#xD;
          -  Contra indication to MRI&#xD;
&#xD;
          -  Person under guardianship or curators&#xD;
&#xD;
          -  Persons of full age deprived of their liberties by a judicial or administrative&#xD;
             decision&#xD;
&#xD;
          -  Major comorbidity considered as a contraindication by the investigator (cancer,&#xD;
             unstable angina, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Céline TARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Céline TARD, MD</last_name>
    <phone>0320445962</phone>
    <email>celine.tard@chru-lille.fr</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebral atrophy</keyword>
  <keyword>MRI</keyword>
  <keyword>cognition</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>tauopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

